Literature DB >> 16957442

Improvement of cystic fibrosis during treatment with isotretinoin.

Jennifer L Buckley1, Mark A Chastain, Robert L Rietschel.   

Abstract

A 15-year-old boy with a history significant for multiple respiratory infections since birth presented for evaluation of acne vulgaris. He was initially prescribed doxycycline, topical tretinoin, and topical clindamycin solution, with the later addition of a benzoyl peroxide preparation to his regimen. The patient returned 6 months later after having been diagnosed with CF (cystic fibrosis) by sweat testing and genetic testing. His skin condition had not responded adequately to prior therapy, so all acne medications were discontinued. The 84-kg patient was started on 80 mg (0.95 mg/kg/d) of isotretinoin (13-cis-retinoic acid) daily. The patient's dose was decreased to 40 mg/d 2 weeks later following an episode of blood in his stool and epistaxis. At the 1- and 2-month follow-up visits, the patient reported improvement in his acne and mentioned that his lung secretions seemed reduced. His acne cleared after 4 months of therapy, so the isotretinoin was discontinued. The patient and his mother noted that no respiratory infections had occurred during the course of therapy. The patient's acne relapsed nearly 2 years later, so isotretinoin was restarted at 60 mg/d. During the next 7 months while on the drug, he experienced no further episodes of epistaxis or bloody stools and his acne had resolved by the end of therapy. The patient and his mother again reported fewer bronchopulmonary secretions and no infections requiring antibiotics during treatment with isotretinoin. This was unusual because he had experienced numerous respiratory infections requiring antibiotics during the prior 2 years. Since discontinuing the drug, the patient has had intermittent pulmonary infections and exacerbations in the symptomatology of his CF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957442     DOI: 10.1111/j.1540-9740.2006.04514.x

Source DB:  PubMed          Journal:  Skinmed        ISSN: 1540-9740


  2 in total

1.  Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

Authors:  Ayman Abdelmaksoud; Anant Patil; Recep Dursun; Selami Aykut Temiz; Erhan Ayhan; Mohamad Goldust; Michelangelo Vestita
Journal:  J Cosmet Dermatol       Date:  2021-06-06       Impact factor: 2.189

2.  Identification of biomarkers in common chronic lung diseases by co-expression networks and drug-target interactions analysis.

Authors:  Mazaher Maghsoudloo; Sadegh Azimzadeh Jamalkandi; Ali Najafi; Ali Masoudi-Nejad
Journal:  Mol Med       Date:  2020-01-17       Impact factor: 6.354

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.